Dystonia - Pipeline Insight, 2024

This “Dystonia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dystonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dystonia Understanding

Dystonia: Overview

Dystonia is a general term for a large group of movement disorders that vary in their symptoms, causes, progression, and treatments. This group of neurological conditions is generally characterized by involuntary muscle contractions that force the body into abnormal, sometimes painful, movements and positions (postures). The muscular contractions may be sustained or come and go (intermittent). Movements may be patterned and twisting, and/or in some cases shaking or quivering (tremulous) resembling a tremor. Dystonia may occur or be worsened when an individual attempts a voluntary action. There are many different causes for dystonia. Genetic as well as non-genetic factors can contribute to the development of these disorders. In some cases, the exact, underlying cause is unknown (idiopathic). The most characteristic finding associated with most forms of dystonia is twisting, repetitive movements that affect the neck, torso, limbs, eyes, face, vocal chords, and/or a combination of these muscle groups. Certain forms such as laryngeal dystonia are not associated with abnormal postures. Treatment for dystonia depends upon several factors including the specific subtype present and can include medications, botulinum toxin injections, physical therapy and surgery.

Dystonia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dystonia pipeline landscape is provided which includes the disease overview and Dystonia treatment guidelines. The assessment part of the report embraces, in depth Dystonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dystonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Dystonia.
• In the coming years, the Dystonia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Dystonia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Dystonia treatment market. Several potential therapies for Dystonia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Dystonia market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Dystonia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Dystonia Emerging Drugs Chapters

This segment of the Dystonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dystonia Emerging Drugs

ABP-450: Daewoong PharmaceuticalABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. When injected at therapeutic doses, ABP-450 causes a chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type-A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. ABP-450 is the same botulinum toxin complex that has been approved in the United States, the European Union and Canada for an aesthetic indication. To support this aesthetic indication, Daewoong’s aesthetic partner completed a Phase 3 head-to-head study with ABP-450 that showed non-inferiority to Botox® at 20 units. Our strategic partner, Daewoong Pharmaceutical Co., Ltd., has also completed head-to-head studies with ABP-450 that showed non-inferiority to Botox® at various doses ranging from 20 units to 360 units.

Dipraglurant: Addex TherapeuticsAddex is developing an extended-release formulation of dipraglurant for the treatment of blepharospasm, a form of dystonia characterized by involuntary muscle contractions and spasms of the eyelid muscles resulting in sustained eyelid closure causing substantial visual disturbance or functional blindness. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.

Dystonia: Therapeutic Assessment

This segment of the report provides insights about the different Dystonia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dystonia

There are approx. 5+ key companies which are developing the therapies for Dystonia. The companies which have their Dystonia drug candidates in the most advanced stage, i.e. phase II include, Daewoong Pharmaceutical.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dystonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dystonia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dystonia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dystonia drugs.

Dystonia Report Insights

• Dystonia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dystonia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dystonia drugs?
• How many Dystonia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dystonia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dystonia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dystonia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daewoong Pharmaceutical
• Addex Therapeutics
• Revance Therapeutics
• CytoDel, Inc.
• Teva Pharmaceutical

Key Products

• ABP-450
• Dipraglurant
• RT002
• Cyto-014
• Deutetrabenazine

This product will be delivered within 2 business days.